We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+6.61%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.51B
AUM Growth
+$203K
Cap. Flow
-$184M
Cap. Flow %
-4.08%
Top 10 Hldgs %
82.68%
Holding
115
New
24
Increased
20
Reduced
23
Closed
20

Top Buys

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$15.8M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$11.2M
3
MET icon
MetLife
MET
+$10.7M
4
TSRO
TESARO, Inc.
TSRO
+$8.14M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$7.5M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$41.4M
2
BLUE
bluebird bio
BLUE
+$13.6M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$12.9M
4
CELG
Celgene Corp
CELG
+$12M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.24M

Sector Composition

Rank Sector Weight
1 Consumer Staples 44.81%
2 Healthcare 28.52%
3 Consumer Discretionary 10.77%
4 Financials 0.73%
5 Industrials 0.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVLN
76
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$2.75M 0.06%
256,400
– –
SNDX icon
77
Syndax Pharmaceuticals
SNDX
$1.7B
$2.74M 0.06%
+200,000
New +$2.08M
LOXO
78
DELISTED
Loxo Oncology, Inc
LOXO
$2.73M 0.06%
65,000
-35,000
-35% -$1.44M
ONCE
79
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$2.67M 0.06%
50,000
– –
CLDX icon
80
Celldex Therapeutics
CLDX
$2.94B
$2.44M 0.05%
45,000
– –
NERV icon
81
Minerva Neurosciences
NERV
$191M
$2.04M 0.05%
31,413
– –
RARE icon
82
Ultragenyx Pharmaceutical
RARE
$2.46B
$2.03M 0.05%
30,000
-20,000
-40% -$1.52M
PRQR icon
83
ProQR Therapeutics
PRQR
$244M
$2M 0.04%
+400,000
New +$1.76M
ADAP
84
DELISTED
Adaptimmune Therapeutics
ADAP
$1.65M 0.04%
300,000
– –
AKAO
85
DELISTED
Achaogen Inc
AKAO
$1.51M 0.03%
60,000
– –
ANAB icon
86
AnaptysBio
ANAB
$1.54B
$1.24M 0.03%
+44,690
New +$1.04M
JUNO
87
CALL
DELISTED
Juno Therapeutics, Inc.
JUNO
$1.11M 0.02%
50,000
-50,000
-50% -$1.07M
KDNY
88
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.07M 0.02%
20,000
– –
IMDX
89
Insight Molecular Diagnostics
IMDX
$141M
$893K 0.02%
7,500
+4,295
+134% +$496K
STML
90
DELISTED
Stemline Therapeutics, Inc.
STML
$855K 0.02%
+100,000
New +$911K
IBRX icon
91
ImmunityBio
IBRX
$7.15B
$799K 0.02%
225,000
– –
NDRM
92
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$664K 0.01%
+25,000
New +$619K
NVAX icon
93
Novavax
NVAX
$1.21B
$640K 0.01%
25,000
– –
XENE icon
94
Xenon Pharmaceuticals
XENE
$6.1B
$600K 0.01%
+150,000
New +$1.18M
DMTX
95
DELISTED
Dimension Therapeutics, Inc
DMTX
$410K 0.01%
234,493
– –
AGEN
96
CALL
Agenus
AGEN
$276M
– –
-25,475
Closed -$2.06M
ALNY icon
97
CALL
Alnylam Pharmaceuticals
ALNY
$38.3B
– –
-200,000
Closed -$7.49M
BIIB icon
98
CALL
Biogen
BIIB
$30.9B
– –
-150,000
Closed -$42.5M
BLUE
99
CALL
DELISTED
bluebird bio
BLUE
– –
-7,720
Closed -$6.17M
CMG icon
100
CALL
Chipotle Mexican Grill
CMG
$43.9B
– –
-5,750,000
Closed -$43.4M
1 2 3
4
5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2017 Portfolio in Review

As of Q1 2017, Artal Group held 115 positions worth $4.51B, up 0% from $4.5B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Artal Group withdrew a net $184M in Q1 2017, closing 20 positions and reducing 23 holdings. Its most notable exit was Celgene Corp, an estimated $12M position sold in full.

By sector, the portfolio is most concentrated in Consumer Staples at 45% of assets, down from 47% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Artal Group opened a new position in Ionis Pharmaceuticals worth $10.1M.

  • Artal Group's largest Q1 2017 buy was Ionis Pharmaceuticals: 250,000 shares worth $10.1M.
  • Artal Group added most to Acceleron Pharma in Q1 2017, an estimated $15.8M increase.
  • Artal Group's biggest Q1 2017 reduction was Incyte, cutting an estimated $41.4M.
  • Artal Group fully exited Celgene Corp in Q1 2017, selling an estimated $12M.
  • Artal Group's ten largest holdings make up 83% of its $4.51B portfolio in Q1 2017.
  • Artal Group opened 24 new positions and closed 20 in Q1 2017.
  • Artal Group's portfolio value rose 0% quarter-over-quarter to $4.51B.

Based on Artal Group's 13F filing for Q1 2017, filed 15 May 2017.